Clinical trial · Interventional
LungPoint ATV for Biopsy in Patients Undergoing Lobectomy
NCT02130115CI-TRIAL-00014410LABELcompletedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to evaluate the safety and performance of the LungPoint ATV System.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| LungPoint ATV System | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Ability to complete procedure using system
- timeFrame
- At completion of procedure
- description
- The proportion of cases (attempted nodules) in which the procedure could be substantially completed by the investigator divided by the number of cases (nodules) for which at least one attempt to pass any LungPoint study device into the bronchoscope was made.
Secondary outcomes (2)
- measure
- Proportion of nodules biopsied yielding tissue sufficient for diagnosis
- timeFrame
- Upon asssessment of histology of tissue sample taken during procedure
- description
- The number of nodules with at least one biopsy sufficient for a tissue diagnosis divided by the number of nodules sampled using the LungPoint ATV system.
- measure
- Number of significant adverse events
- timeFrame
- Up through lobectomy of lobe at end of procedure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 21 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1. Surgical candidates age 21-75 years at screening 2. Known or suspected lung cancer or intrapulmonary metastatic disease with SPN greater than 10 mm and less than 40mm in largest dimension 3. No known endobronchial tumor 4. Tumor located anywhere in parenchymal tissue \>1 cm from pleura and accessible bronchoscopically through a POE. 5. Willing to participate in all aspects of study protocol for duration of study 6. Able to understand study requirements 7. Signs study-related informed consent document Exclusion Criteria: 1. Any contraindication to bronchoscopy, for example: (a.) Untreatable life-threatening arrhythmias, (b.) Inability to adequately oxygenate the patient during the procedure, (c.) Acute respiratory failure with hypercapnia (unless the patient is intubated and ventilated), (d.) Recent myocardial infarction, (e.) Previously diagnosed high-grade tracheal obstruction, (f.) Uncorrectable coagulopathy. 2. Known coagulopathy 3. Platelet dysfunction or platelet count \< 100 x 103 cells/mm3 4. History of major bleeding with bronchoscopy 5. Pulmonary hypertension with mean PAP \>25 mm 6. Moderate-to-severe pulmonary fibrosis 7. Moderate to severe emphysema or COPD with FEV1 \<60% predicted or RV \>200% predicted 8. Bullae \>5 cm located in vicinity of target SPN or ATV tunnel 9. Any other severe or life-threatening comorbidity that could increase the risk of bronchoscopic biopsy or ATV tunneling, for example: (a.) ASA class \> 3, (b.) \> stage 3 heart failure, (c.) severe cachexia, (d.) severe respiratory insufficiency or hypoxia 10. Ongoing systemic infection 11. Contraindication to general anesthesia 12. Chronic use of anticoagulants (e.g., heparin, Warfarin) or antiplatelet agents (e.g. aspirin, clopidogrel) 13. Participation in any other study in last 30 days 14. Prior thoracic surgery on the same side of the lung as the SPN 15. Breastfeeding women or females of childbearing potential with a positive pregnancy test prior to the procedure or the intent to become pregnant during the study. 16. Life expectancy of less than one year. 17. Patients with known intrapulmonary metastases of extrapulmonary cancer/tumors
References
Publications (1)
- DERIVEDHerth FJ, Eberhardt R, Sterman D, Silvestri GA, Hoffmann H, Shah PL. Bronchoscopic transparenchymal nodule access (BTPNA): first in human trial of a novel procedure for sampling solitary pulmonary nodules. Thorax. 2015 Apr;70(4):326-32. doi: 10.1136/thoraxjnl-2014-206211. Epub 2015 Mar 6. PMID 25746631